Search | Clinical Trials Finder

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: CIN-103, Placebo; Drug
Lead sponsor: CinPhloro Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more

Conditions: Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions: NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Healthy Lifetime Non-smokers
Interventions: Propylene Glycol, vegetable glycerin, PG+VG; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 51
States / cities: Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more

Conditions: Thrombocytopenia
Interventions: Avatrombopag; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2018 – 2019
U.S. locations: 41
States / cities: Chandler, Arizona • Lancaster, California • Los Angeles, California + 37 more

Conditions: Post Operative Pain, Osteoarthritis, Knee
Interventions: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 35 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Alpha-1 MP, alpha-1 proteinase inhibitor (human); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more

Conditions: Hot Flashes
Interventions: Fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 65
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: HIV Infections
Interventions: Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Miami, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05231023, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Chula Vista, California • Fort Meyers, Florida • Miami, Florida + 2 more

Conditions: Brain and Central Nervous System Tumors
Interventions: HSPPC-96, Temozolomide, Standard Surgical Resection; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Sickle Cell Disease
Interventions: INCB059872; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Miami, Florida • Tamarac, Florida • Chicago, Illinois + 3 more

Conditions: Advanced Solid Tumor
Interventions: DB-1305/BNT325, Pembrolizumab, BNT327; Drug · Combination Product
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 42
States / cities: Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more

Conditions: Heart Failure
Interventions: Medtronic PrimeADVANCED Neurostimulator; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Indianapolis, Indiana • Allentown, Pennsylvania + 3 more

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: Botox; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Enterovirus, Rhinovirus
Interventions: Nitazoxanide, Placebo; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Hot Springs, Arkansas + 36 more

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 46
States / cities: Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more

Conditions: Alzheimer Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 47
States / cities: Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more

Conditions: Colorectal Cancer
Interventions: Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 35
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more

Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions: Perampanel Oral Suspension, Perampanel Tablet; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle; Drug
Lead sponsor: Ralexar Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more

Conditions: ARDS, Human, Covid19
Interventions: Longeveron Mesenchymal Stem Cells (LMSCs), Placebo; Biological · Other
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina

Search by objective public record fields.

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

Evaluation of Acute and Subacute Effects of Nicotine Free Electronic Cigarette(NCFE) Vapors

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

ZYNRELEF for Pain Management in Total Knee Arthroplasty

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure

Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

A Study in Subjects With Moderate Atopic Dermatitis

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)